Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound betamethasone is a pharmaceutical drug that combines two forms of the synthetic glucocorticoid betamethasone: betamethasone sodium phosphate and betamethasone dipropionate. This combination is designed to provide both rapid onset and prolonged anti-inflammatory effects. Betamethasone sodium phosphate is a soluble agent for quick absorption, while betamethasone dipropionate is a slightly soluble drug that acts as a reservoir for sustained release. It functions by binding to glucocorticoid receptors, affecting the transcription of proteins involved in the inflammatory response, thereby reducing inflammation, pain, and swelling. It is being investigated for various conditions including acute gout, pain after supraspinatus tendon repair, severe alopecia areata, frozen shoulder, vitiligo, and for postoperative pain management in several surgical procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound betamethasone.